Earlybird registration deadline: 28 September 2018
This training event aims to provide a comprehensive overview of the pre-clinical drug discovery process. Designed and delivered by experts from industry and academia, the event is suitable for recent graduates, PhD students and early career scientists interested in working in the pre-clinical drug discovery industry.
The course will focus on small molecule target identification and validation, hit-to-lead and lead optimisation, as well as on pre-clinical drug development and toxicology. ‘Key aspects of modern drug discovery’ will comprise lectures, case studies, group discussions and a drinks reception to encourage networking and collaboration among delegates and speakers.
Speakers include:
This training event aims to provide a comprehensive overview of the pre-clinical drug discovery process. Designed and delivered by experts from industry and academia, the event is suitable for recent graduates, PhD students and early career scientists interested in working in the pre-clinical drug discovery industry.
The course will focus on small molecule target identification and validation, hit-to-lead and lead optimisation, as well as on pre-clinical drug development and toxicology. ‘Key aspects of modern drug discovery’ will comprise lectures, case studies, group discussions and a drinks reception to encourage networking and collaboration among delegates and speakers.
Speakers include:
- Rick Davies, AstraZeneca
- Jacqui Piner, GSK
- John Unitt, Sygnature Discovery
- Heather Wallace, University of Aberdeen
- Rupert Satchell, Sygnature Discovery
- Andy Davis, AstraZeneca
- John Ladbury, University of Leeds
